ABSTRACT DNA sequence analysis recently identified the novel SARS-CoV-2 variant B.1.526 that is spreading at an alarming rate in the New York City area. Two versions of the variant were identified, both with the prevalent D614G mutation in the spike protein, together with four novel point mutations and with an E484K or S477N mutation in the receptor-binding domain, raising concerns of possible resistance to vaccine-elicited and therapeutic antibodies. We report that convalescent-phase sera and vaccine-elicited antibodies retain full neutralizing titer against the S477N B.1.526 variant and neutralize the E484K version with a modest 3.5-fold decrease in titer compared to D614G. The E484K version was neutralized with a 12-fold decrease in titer by the REGN10933 monoclonal antibody, but the combination cocktail with REGN10987 was fully active. The findings suggest that current vaccines and Regeneron therapeutic monoclonal antibodies will remain protective against the B.1.526 variants. The findings further support the value of widespread vaccination.
【저자키워드】 SARS-CoV-2, neutralization, Spike protein, B.1.526, Pfizer BNT162b2, Moderna mRNA-1273, REGN10933, REGN10987, 【초록키워드】 antibodies, Vaccine, vaccination, Mutation, antibody, monoclonal antibody, variant, SARS-CoV-2 variant, variants, New York City, Spike protein, D614G mutation, Receptor-binding domain, titer, sera, therapeutic, D614G, E484K, REGN10987, Protective, Neutralizing titer, Combination, Analysis, Point mutation, Support, S477N, DNA sequence, Regeneron, widespread, decrease, prevalent, neutralize, neutralized, the spike protein, the receptor-binding domain, raising, 【제목키워드】 Identified,